Glenn Sblendorio

Glenn P.
Sblendorio is currently President & Chief Executive Officer at Ophthotech Corp.
(New Jersey), Chairman at Mineralys Therapeutics, Inc., Chairman at Nanoscope Therapeutics, Inc., and Director at 4D Molecular Therapeutics, Inc. Former roles include Chief Executive Officer & Managing Director at Mpm Capital Advisors LLC from 1998 to 2000, Chief Executive Officer & Director at IVERIC bio, Inc. from 2021 to 2023, Chairman at NuLens Ltd., President, CFO, Treasurer & Director at The Medicines Co. from 2013 to 2016, Independent Director at Intercept Pharmaceuticals, Inc. from 2014 to 2023, Independent Director at Amicus Therapeutics, Inc. from 2006 to 2026, Managing Director at Sony Interactive Entertainment LLC from 1992 to 1996, Head-Finance & Controller at Amgen, Inc., Chief Financial Officer & Executive Vice President at Oldtech, Inc. from 2002 to 2005, Chief Financial Officer at Hoffmann-La Roche, Inc., Chief Financial Officer & Vice President-Finance at Roche Molecular Systems, Inc. from 1992 to 1993, and Chief Financial Officer at Millennium Venture Management LLC.
Education includes an MBA from Fairleigh Dickinson University conferred in 1985 and an undergraduate degree from Pace University conferred in 1978.